NCT01506752

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: Male
• Age: 20 Years – 44 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the bioequivalence of improved and current orally disintegrating E2020 10 mg tablets as a single dose in Japanese healthy adult males for each of two administration methods (with/without water).

Conditions

• Healthy Adult

Interventions

Type	Name	Description
DRUG	Donepezil Hydrochloride	improved orally disintegrating E2020 10 mg tablet without water.
DRUG	Donepezil Hydrochloride	current orally disintegrating E2020 10 mg tablet without water.
DRUG	Donepezil Hydrochloride	improved orally disintegrating E2020 10 mg tablet with water.
DRUG	Donepezil Hydrochloride	current orally disintegrating E2020 10 mg tablet with water

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2012-01-10
• Last updated: 2012-06-27

Locations

1 site across 1 country: Japan